An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer

Heather J. Dalton; Xinhua Yu; Lilian Hu; Daniel S. Kapp; Ivor Benjamin; Bradley J. Monk; John K. Chan

doi:10.1016/j.ygyno.2011.09.028

An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.09.028 ◽

2012 ◽

Vol 124 (2) ◽

pp. 199-204 ◽

Cited By ~ 16

Author(s):

Heather J. Dalton ◽

Xinhua Yu ◽

Lilian Hu ◽

Daniel S. Kapp ◽

Ivor Benjamin ◽

...

Keyword(s):

Ovarian Cancer ◽

Economic Analysis ◽

Advanced Ovarian Cancer ◽

Weekly Paclitaxel ◽

Dose Dense

Download Full-text

Dose-Dense Weekly Paclitaxel and Carboplatin Is More Cost-Effective Than Bevacizumab Plus Triweekly Paclitaxel and Carboplatin for the Primary Treatment of Advanced Ovarian Cancer

Annals of Oncology ◽

10.1016/s0923-7534(20)33576-6 ◽

2012 ◽

Vol 23 ◽

pp. ix320-ix321

Author(s):

K. Harano ◽

T. Shiroiwa ◽

M. Watanabe ◽

K. Suzuki ◽

T. Fukuda ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Cost Effective ◽

Primary Treatment ◽

Weekly Paclitaxel ◽

Dose Dense

Download Full-text

An economic analysis of intravenous carboplatin plus dose-dense weekly paclitaxel versus intravenous carboplatin plus every three-weeks paclitaxel in the upfront treatment of ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.12.035 ◽

2011 ◽

Vol 120 ◽

pp. S13 ◽

Cited By ~ 1

Author(s):

H. Dalton ◽

X. Yu ◽

L. Hu ◽

B. Monk ◽

I. Benjamin ◽

...

Keyword(s):

Ovarian Cancer ◽

Economic Analysis ◽

Weekly Paclitaxel ◽

Dose Dense

Download Full-text

Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer

Case Medical Research ◽

10.31525/ct1-nct04135521 ◽

2019 ◽

Author(s):

Keyword(s):

Ovarian Cancer ◽

Intraperitoneal Chemotherapy ◽

Advanced Ovarian Cancer ◽

First Line ◽

Dose Dense ◽

Line Chemotherapy

Download Full-text

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

Download Full-text

Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.194 ◽

2015 ◽

Vol 137 ◽

pp. 79

Author(s):

N.D. Fleming ◽

R.L. Coleman ◽

C.S. Tung ◽

M.F. Munsell ◽

A.K. Sood

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line ◽

Dose Dense ◽

First Line Treatment

Download Full-text

408 Dose-dense paclitaxel and carboplatin plus bevacizumab is an effective and a tolerable first-line regimen for advanced ovarian cancer

10.1136/ijgc-2020-igcs.353 ◽

2020 ◽

Author(s):

H Komazaki ◽

K Takahashi ◽

H Tanabe ◽

Y Shoburu ◽

A Izumi ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

First Line ◽

Dose Dense

Download Full-text

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(09)61157-0 ◽

2009 ◽

Vol 374 (9698) ◽

pp. 1331-1338 ◽

Cited By ~ 494

Author(s):

Noriyuki Katsumata ◽

Makoto Yasuda ◽

Fumiaki Takahashi ◽

Seiji Isonishi ◽

Toshiko Jobo ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Open Label ◽

Phase 3 ◽

Dose Dense ◽

Randomised Controlled

Download Full-text

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?

Journal of Gynecologic Oncology ◽

10.3802/jgo.2018.29.e96 ◽

2018 ◽

Vol 29 (6) ◽

Cited By ~ 7

Author(s):

Matilda X. Lee ◽

David SP Tan

Keyword(s):

Ovarian Cancer ◽

Adjuvant Chemotherapy ◽

Chemotherapy Regimen ◽

Advanced Ovarian Cancer ◽

Weekly Paclitaxel ◽

Adjuvant Chemotherapy Regimen

Download Full-text

First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5071 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5071-5071

Author(s):

G. Oskay-Özcelik ◽

R. Richter ◽

K. Pietzner ◽

H. Hindenburg ◽

H. L. Sommer ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

German Society ◽

Life Data ◽

Multicenter Phase ◽

Dose Dense

Download Full-text

Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps5612 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS5612-TPS5612 ◽

Cited By ~ 4

Author(s):

Robert Michael Wenham ◽

Sachin M. Apte ◽

Mian M. Shahzad ◽

Jae K Lee ◽

Denise Dorman ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Recurrent Ovarian Cancer ◽

Weekly Paclitaxel ◽

Platinum Resistant ◽

Dose Dense

Download Full-text